July 12, 2017 08:46 AM EDT

Ocular Therapeutix's last-minute gambit fails to salvage its second FDA application, shares plunge

An 11th hour bid by Ocular Therapeutix to salvage its FDA application for their drug/device eye treatment Dextenza got shot down in a hurry on …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Oc­u­lar Ther­a­peu­tix's last-minute gam­bit fails to sal­vage its sec­ond FDA ap­pli­ca­tion, shares plunge